The third-quarter earnings season is upon us with major biopharma companies reporting mixed financial results, providing a litmus test for the state of the industry and the opportunity to revise expectations for the final quarter of 2023 and beyond. There have been some pleasant and unpleasant surprises for investors this week as clear Q3 winners and losers have emerged.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,